Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for advanced or metastatic angiosarcoma (phase II)
2004-004546-41Phase 2Completed
- Sponsor
- Helsinki University Hospital
- Start
- Jan 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in angiosarcoma, sponsored by Helsinki University Hospital. Primary endpoint: Objective response or clinical benefit rate. Started Jan 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on 2004-004546-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004546-41.